Welcome to our dedicated page for Tg Therapeutics news (Ticker: TGTX), a resource for investors and traders seeking the latest updates and insights on Tg Therapeutics stock.
TG Therapeutics Inc (NASDAQ: TGTX) is a biopharmaceutical innovator advancing therapies for B-cell malignancies and autoimmune disorders. This dedicated news hub provides investors and industry professionals with essential updates on clinical developments, regulatory milestones, and corporate strategies.
Access real-time announcements including trial results, FDA submissions, and partnership agreements. Our curated collection ensures you never miss critical updates about ublituximab (BRIUMVI), PI3K delta inhibitors, or emerging pipeline candidates.
Key content categories include quarterly earnings reports, scientific conference presentations, manufacturing updates. All materials are sourced directly from company filings and verified industry publications.
Bookmark this page for streamlined tracking of TGTX's progress in developing glycoengineered antibody therapies and maintaining compliance with financial disclosure requirements. Check regularly for authoritative updates on this NASDAQ-listed biotech pioneer.
TG Therapeutics (NASDAQ: TGTX) has announced upcoming presentations featuring BRIUMVI® (ublituximab-xiiy) data at the 2025 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting in Phoenix, Arizona from May 28-31, 2025. The presentations include three key studies:
1. A platform presentation on the relationship between serum immunoglobulin levels and infections during long-term ublituximab treatment by Dr. Bruce Cree
2. A poster on infusion tolerability from the ENAMOR real-world observational survey presented by Dr. Edward Fox
3. A poster updating safety and tolerability data of 30-minute ublituximab infusions from the ENHANCE study by Dr. John Foley
All presentations are scheduled for May 29, 2025, and the data will be made available on TG Therapeutics' website after the presentations.
TG Therapeutics has scheduled a conference call for Monday, May 5, 2025, at 8:30 AM ET to discuss their first quarter 2025 financial results and provide a business outlook for the remainder of the year. The call will be hosted by Michael S. Weiss, Chairman and Chief Executive Officer.
Participants can join the call using the following dial-in numbers:
- U.S.: 1-877-407-8029
- International: 1-201-689-8029
A live webcast will be available on the Events page in the Investors & Media section of www.tgtherapeutics.com. An audio recording will remain accessible for 30 days after the call on the company website. Financial results will be released via press release before the conference call.
TG Therapeutics (NASDAQ: TGTX) presented data for BRIUMVI® (ublituximab-xiiy) in treating relapsing forms of multiple sclerosis (RMS) at the American Academy of Neurology 2025 annual meeting. The ENHANCE trial demonstrated that a single 600 mg dose of BRIUMVI on Day 1 was well-tolerated, leading the company to consider a registration-directed trial to combine the currently approved Day 1 and Day 15 doses into a single administration.
Two key presentations were featured:
- Efficacy and Safety of Modified Ublituximab Regimen (ENHANCE) by Dr. John Foley
- Five-year Ublituximab results in Relapsing Multiple Sclerosis from ULTIMATE I and II Studies' open-label extension by Dr. Bruce Cree
TG Therapeutics (NASDAQ: TGTX) presented three significant data sets for BRIUMVI® (ublituximab-xiiy) in treating relapsing forms of multiple sclerosis (RMS) at the American Academy of Neurology 2025 annual meeting.
Key findings include:
- The ENAMOR survey, covering ~400 patients across 21 MS centers, showed improved tolerability and lower infusion-related reactions compared to Phase 3 trials
- 90% of surveyed patients received acetaminophen pre-medication, potentially explaining the better tolerance rates
- The company announced ENABLE, a new Phase 4 96-week observational study, which will track approximately 500 patients across 100 US MS centers
- Five-year BRIUMVI treatment data showed consistent serious infection rates with Phase 3 trials and no Progressive Multifocal Leukoencephalopathy (PML) cases
TG Therapeutics (NASDAQ: TGTX) has announced the publication of two significant journal articles focusing on BRIUMVI® (ublituximab-xiiy) in multiple sclerosis (MS) treatment. The first publication in Frontiers in Immunology presents a case series of seven MS patients who switched to BRIUMVI from other anti-CD20 therapies due to efficacy or tolerability issues.
The second article, published in CNS DRUGS, examines the evolution of anti-CD20 treatments for MS, discussing key characteristics such as scaffold, mechanism of action, and Fc engineering that may influence therapeutic efficacy and patient experience.
Michael S. Weiss, Executive Chairman and CEO, emphasized these publications provide rationale for switching patients within the CD20 class before abandoning it entirely. The company continues to study this phenomenon through their ongoing ENHANCE and ENABLE studies to further validate these initial findings.
TG Therapeutics (NASDAQ: TGTX) has announced upcoming presentations featuring BRIUMVI® (ublituximab-xiiy) data for relapsing multiple sclerosis (RMS) at the American Academy of Neurology 2025 annual meeting in San Diego (April 5-9, 2025).
The presentations include five poster sessions focusing on:
- Long-term ublituximab treatment's impact on immunoglobulin levels and serious infections
- Real-world infusion tolerability (ENAMOR survey)
- ENABLE Phase 4 observational study
- Five-year results from ULTIMATE I and II studies' open-label extension
- Modified ublituximab regimen (ENHANCE) efficacy and safety
Key researchers presenting include Dr. Bruce Cree from UC San Francisco's Weill Institute for Neurosciences, Dr. Ed Fox from TG Therapeutics, and Dr. John Foley from Rocky Mountain Multiple Sclerosis.
FAQ
What is the current stock price of Tg Therapeutics (TGTX)?
What is the market cap of Tg Therapeutics (TGTX)?
